Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

U. Koehl; C. Kalberer; J. Spanholtz; D. A. Lee; J. S. Miller; S. Cooley; M. Lowdell; L. Uharek; H. Klingemann; A. Curti; W. Leung; E. Alici

doi:10.1080/2162402X.2015.1115178

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

U. Koehl, C. Kalberer, J. Spanholtz, D. A. Lee, J. S. Miller, S. Cooley, M. Lowdell, L. Uharek, H. Klingemann, A. Curti, W. Leung, E. Alici

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

75 Scopus citations

Abstract

ABSTRACT: Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.

Original language	English (US)
Journal	OncoImmunology
Volume	5
Issue number	4
DOIs	https://doi.org/10.1080/2162402X.2015.1115178
State	Published - Apr 2 2016

Bibliographical note

Publisher Copyright:
© 2016 The Author(s). Published with license by Taylor & Francis Group, LLC

Keywords

Clinical NK cell studies
ex vivo expansion
manufacturing of NK cell products
quality control

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1080/2162402X.2015.1115178

OpenUrl availability

Full text

Cite this

@article{5221d49bc3b84f769a088f7b2855fae3,

title = "Advances in clinical NK cell studies: Donor selection, manufacturing and quality control",

abstract = "ABSTRACT: Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.",

keywords = "Clinical NK cell studies, ex vivo expansion, manufacturing of NK cell products, quality control",

author = "U. Koehl and C. Kalberer and J. Spanholtz and Lee, {D. A.} and Miller, {J. S.} and S. Cooley and M. Lowdell and L. Uharek and H. Klingemann and A. Curti and W. Leung and E. Alici",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s). Published with license by Taylor & Francis Group, LLC",

year = "2016",

month = apr,

day = "2",

doi = "10.1080/2162402X.2015.1115178",

language = "English (US)",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

TY - JOUR

T1 - Advances in clinical NK cell studies

T2 - Donor selection, manufacturing and quality control

AU - Koehl, U.

AU - Kalberer, C.

AU - Spanholtz, J.

AU - Lee, D. A.

AU - Miller, J. S.

AU - Cooley, S.

AU - Lowdell, M.

AU - Uharek, L.

AU - Klingemann, H.

AU - Curti, A.

AU - Leung, W.

AU - Alici, E.

PY - 2016/4/2

Y1 - 2016/4/2

N2 - ABSTRACT: Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.

AB - ABSTRACT: Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.

KW - Clinical NK cell studies

KW - ex vivo expansion

KW - manufacturing of NK cell products

KW - quality control

UR - http://www.scopus.com/inward/record.url?scp=84962886163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962886163&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1115178

DO - 10.1080/2162402X.2015.1115178

M3 - Review article

C2 - 27141397

AN - SCOPUS:84962886163

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 4

ER -

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this